Advertisement

Table of Contents

July 16, 2015; 126 (3)

INSIDE BLOOD COMMENTARIES

PLENARY PAPER

  • International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
    Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, Steve Songer, Lela M. Lucy, C. L. Beach and Hartmut Döhner

PERSPECTIVES

REVIEW ARTICLE

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS

PLATELETS AND THROMBOPOIESIS

RED CELLS, IRON, AND ERYTHROPOIESIS

THROMBOSIS AND HEMOSTASIS

TRANSFUSION MEDICINE

TRANSPLANTATION

  • Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy
    Yasuyuki Arai, June Takeda, Kazunari Aoki, Tadakazu Kondo, Satoshi Takahashi, Yasushi Onishi, Yukiyasu Ozawa, Nobuyuki Aotsuka, Yasuji Kouzai, Hirohisa Nakamae, Shuichi Ota, Chiaki Nakaseko, Hiroki Yamaguchi, Koji Kato, Yoshiko Atsuta and Akiyoshi Takami on behalf of the AML and MDS Working Group of the Japan Society for Hematopoietic Cell Transplantation

BLOOD WORK

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS